CRO Quanticate has named David Hukin as the its new senior director of pharmacovigilance. David has a PhD in Cell Physiology and Biophysics and 15 years’ experience in the pharmaceutical industry, with more than 14 years dedicated to the pharmacovigilance sector. He has worked in small, medium-size and large speciality pharma/biotech companies and has gained pre- and post-marketing experience in a range of therapeutic areas including gastroenterology, hepatology, neurology, oncology and psychiatric conditions as well as advanced therapy medicinal products (ATMPs) and orphan drug indication products for rare diseases.